Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics presents EIK1003, EIK1004 and EIK1005 clinical data at ESMO Congress

Mixed Impact 3 of 5 other Written later

Eikon Therapeutics presented updated and initial clinical data from its PARP1 and WRN helicase programs at the 2026 ESMO Congress on October 23, 2026, and issued a press release on the results. The filing reports objective response rates alongside frequent Grade 3 or higher adverse events, and it contains no financial results, so the effect on shareholders is mixed and depends on later development steps.

Key points

  • EIK1003 Cohort 1C with weekly paclitaxel: objective response rate 26.4% (14/53); Grade 3 or higher adverse events in 80.3% (49/61) of participants
  • EIK1003 monotherapy Cohort 1A: objective response rate 14.3% (7/49) among efficacy-evaluable participants, with data cutoff October 1, 2026
  • EIK1004 monotherapy: objective response rate 12.1% (7/58); Grade 3 or higher adverse events in 17.6% (12/68) of participants
  • Further EIK1003 Cohort 1D and EIK1004 docetaxel combination results are expected in the second half of 2027

The filing

CompanyEikon Therapeutics, Inc. (EIKN)
Form8-K, current report
Filed with the SECOct 23, 2026, 9:15 AM ET
Accession number0001193125-26-429549

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.